gepirone   Click here for help

GtoPdb Ligand ID: 12930

Synonyms: BMY-13805 | BMY13805 | Exxua® | MJ-13805 | MJ13805 | ORG-13011 | Travivo (gepirone extended-release)
Approved drug
gepirone is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Gepirone (BMY-13805) is a 5-HT1A receptor agonist [5].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 68.58
Molecular weight 359.47
XLogP 0.71
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1
Isomeric SMILES CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
InChI InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
InChI Key QOIGKGMMAGJZNZ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Gepirone was evaluated as a treament for psychiatric conditions including major depressive disorder [4], generalised anxiety disorder and hypoactive sexual desire disorder [3] and drug dependency. The FDA approved gepirone as a treatment for major depressive disorder in September 2023. The trade name Exxua is an extended-release formulation that was previously known as Travivo.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00000189 Gepirone vs Placebo in Treatment of Cocaine Dependence - 3 Phase 2 Interventional University of Pennsylvania